Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S.…
6 months ago
Pharmaceutical Executive Daily: FDA Limits Regulations of Non-Medical Fitness Devices
In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry leaders examine how humans an…
6 months ago
Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million
6 months ago
Pharmaceutical Executive Daily: Alnylam Invests $250 Million in Manufacturing Facility
In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Therap…
6 months, 1 week ago
Pharmaceutical Executive Daily: Wegovy Pill Becomes Available
In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, clears a new therapy to prev…
6 months, 1 week ago
Pharmaceutical Executive Daily: FDA Approves Wegovy Pill
In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Velo fo…
6 months, 2 weeks ago
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 bi…
6 months, 3 weeks ago
Scaling Sustainability: A Big Pharma Formula
In this enlightening conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance …
6 months, 3 weeks ago
Pharmaceutical Executive Daily: US Senate Passes Biosecure Act
In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. Se…
6 months, 3 weeks ago
Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a v…
6 months, 3 weeks ago